Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma

Elizabeth C. Smyth (Lead / Corresponding author), Russell D. Petty

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)97-98
Number of pages2
JournalThe Lancet
Volume392
Issue number10142
Early online date4 Jun 2018
DOIs
Publication statusPublished - 14 Jul 2018

Cite this

Smyth, Elizabeth C. ; Petty, Russell D. / Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma. In: The Lancet. 2018 ; Vol. 392, No. 10142. pp. 97-98.
@article{384c73994d4d42cd9cb2441820fce76e,
title = "Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma",
author = "Smyth, {Elizabeth C.} and Petty, {Russell D.}",
note = "ECS has received honoraria from Five Prime Therapeutics, Gritstone Oncology, and Celgene for advisory roles, from Servier for giving a lecture about gastro-oesophageal cancer, and from BMS for an education day on treatments in melanoma. RDP has received honoraria from Bristol-Myers Squibb and Roche for advisory roles and from Pfizer for lectures on precision cancer medicine; RDP has also received grants for clinical research from Bristol-Myers Squibb, AstraZeneca, Merck Serono, Merck & Co, Five Prime Therapeutics, and ARMO Biosciences; this research involves immunotherapies in gastric and oesophageal cancer but is not related to the clinical trial discussed in this Comment",
year = "2018",
month = "7",
day = "14",
doi = "10.1016/S0140-6736(18)31277-7",
language = "English",
volume = "392",
pages = "97--98",
journal = "Lancet",
issn = "0140-6736",
publisher = "ELSEVIER SCIENCE INC",
number = "10142",

}

Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma. / Smyth, Elizabeth C. (Lead / Corresponding author); Petty, Russell D.

In: The Lancet, Vol. 392, No. 10142, 14.07.2018, p. 97-98.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma

AU - Smyth, Elizabeth C.

AU - Petty, Russell D.

N1 - ECS has received honoraria from Five Prime Therapeutics, Gritstone Oncology, and Celgene for advisory roles, from Servier for giving a lecture about gastro-oesophageal cancer, and from BMS for an education day on treatments in melanoma. RDP has received honoraria from Bristol-Myers Squibb and Roche for advisory roles and from Pfizer for lectures on precision cancer medicine; RDP has also received grants for clinical research from Bristol-Myers Squibb, AstraZeneca, Merck Serono, Merck & Co, Five Prime Therapeutics, and ARMO Biosciences; this research involves immunotherapies in gastric and oesophageal cancer but is not related to the clinical trial discussed in this Comment

PY - 2018/7/14

Y1 - 2018/7/14

U2 - 10.1016/S0140-6736(18)31277-7

DO - 10.1016/S0140-6736(18)31277-7

M3 - Comment/debate

AN - SCOPUS:85047884690

VL - 392

SP - 97

EP - 98

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 10142

ER -